PapersPMID:37181363
The clinical efficacy of melatonin in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.
No finding here moved its endpoint.
What did not
1 findingHow to read these marks →“No statistically significant effects were revealed between the groups regarding changes in ESR (MD −0.12, 95% CI −0.64 to 0.39, p = 0.64; I2 0%, p for heterogeneity = 0.67) and NLR (MD 7.31, 95% CI −15.21 to 29.84, p = 0.52; I2 87%, p for heterogeneity < 0.01) after melatonin administration.”
- Study
- meta-analysis
- Effect
- −0.12 mean difference, 95% CI −0.64 to 0.39
- Population
- hospitalized adults with COVID-19 receiving melatonin plus standard care versus control (predominantly standard care alone, two trials placebo-controlled)
Study record
- Design
- meta-analysis
- Species
- human
- Population
- 718 hospitalized (mostly) adult COVID-19 patients across 9 RCTs; melatonin plus standard care vs control (predominantly standard care alone, two trials placebo-controlled)
- Participants
- 718
- Comparator
- placebo
- Duration
- not reported
- Endpoints measured
- 9
melatonin